New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers

NCT ID NCT05605496

Ongoing Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combination. The goal is to see if more tumors respond or stop growing for at least 12 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS METASTATIC SOLID TUMORS

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France
Centre Léon Bérard

Lyon, 69008, France
Institut Claudius Regaud (IUCT Oncopole)

Toulouse, 31059, France
Institut Curie

Paris, 75005, France
Institut de Cancérologie Strasbourg Europe (ICANS)

Strasbourg, 67033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.